Valuation: PREDILIFE

Market Cap 4.74M 5.47M 4.41M 4.06M 7.66M 520M 7.75M 51.87M 20.36M 260M 20.54M 20.08M 862M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 9.51M 10.98M 8.87M 8.16M 15.4M 1.04B 15.57M 104M 40.9M 523M 41.25M 40.34M 1.73B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 month-48.50%
3 months-59.73%
6 months-62.03%
Current year-60.13%
1 week 1.2
Extreme 1.2
1.2
1 month 0.9
Extreme 0.9
2.33
Current year 0.9
Extreme 0.9
4
1 year 0.9
Extreme 0.9
4
3 years 0.9
Extreme 0.9
24
5 years 0.9
Extreme 0.9
24
10 years 0.9
Extreme 0.9
24
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
7/27/23 Buy

Chief Executive Officer

1,200 0.0328%
3/23/22 Sell

Chief Executive Officer

3,000 0.0820%
3/9/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-65.32%-79.49% 5.47M
+0.20%+9.04%+122.62%+260.18% 3.93B
-0.56%-17.16%+84.53%+80.63% 3.71B
-3.38%+28.49%+254.09%+309.91% 2.35B
+1.15%+5.65%-26.06%-34.64% 2.24B
-0.46%-4.82%+57.82%-40.06% 1.94B
-0.31%-2.73%+173.93%-44.26% 946M
+0.36%+10.22%-4.59%+10.87% 898M
-0.73%+1.89%-39.05%-11.75% 513M
+0.24%+22.59%+1.82% - 508M
Average -0.35%+6.27%+55.98%+50.15% 1.7B
Weighted average by Cap. -0.46%+3.77%+93.17%+112.28%

Financials

2024 2025
Net sales 493K 569K 460K 423K 798K 54.15M 807K 5.4M 2.12M 27.09M 2.14M 2.09M 89.73M 836K 965K 779K 717K 1.35M 91.76M 1.37M 9.16M 3.59M 45.91M 3.62M 3.54M 152M
Net income -4.26M -4.92M -3.98M -3.66M -6.9M -468M -6.98M -46.72M -18.34M -234M -18.49M -18.09M -776M -3.93M -4.54M -3.67M -3.37M -6.37M -432M -6.44M -43.1M -16.92M -216M -17.06M -16.69M -716M
Net Debt 3.54M 4.09M 3.3M 3.03M 5.73M 388M 5.79M 38.76M 15.21M 194M 15.34M 15.01M 644M 4.78M 5.52M 4.45M 4.1M 7.73M 525M 7.82M 52.34M 20.54M 262M 20.72M 20.26M 869M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
26-08-05 €1.200 0.00% 0
26-08-04 €1.200 0.00% 258
26-08-03 €1.200 0.00% 0
26-07-31 €1.200 -4.00% 1,179
26-07-30 €1.250 +4.17% 2,183

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock